New cancer drug OC-001 tested in advanced tumors – trial ends early
NCT ID NCT04260802
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested an experimental drug called OC-001, given alone or with the immunotherapy avelumab, in 73 people with various advanced or metastatic cancers (like lung, breast, and bladder cancer). The main goals were to check safety and how the drug moves through the body. The study was terminated early, so while it gathered some safety data, it did not fully evaluate effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- OC-001 (an experimental drug) alone or combined with avelumab (an immunotherapy)
- What this could lead to
- If successful, this could point toward a new treatment option for several advanced cancers that have stopped responding to standard therapies.
- What could go wrong
- This was an early-phase trial that was terminated, so results are limited. The drug may not prove effective or safe in larger studies, and side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec, H2X 0A9, Canada
-
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2, Canada
-
Jewish General Hospital - Clinical Research Unit
Montreal, Quebec, H3T 1E2, Canada
-
Ottawa Hospital Cancer Centre (OHRI)
Ottawa, Ontario, Canada
-
Princess Margaret Hospital
Toronto, Ontario, M5G 2C1, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new protein drug shield kids with cancer from dangerous infections?
- Can a Chest-Injected drug drain Cancer's fluid trap?
- Can two drugs together fight Hard-to-Treat bone and Soft-Tissue cancers?
- Can a cancer vaccine prime the body to better fight liver tumors?
- Can a Three-Drug cocktail shrink stomach tumors before surgery?
- Can a radioactive tracer reveal whether immunotherapy is working?